NEPH · Nephros, Inc.

Performance Summary

Nephros, Inc. delivered strong financial results for fiscal year 2025, reporting total net revenues of $18.8 million, a 33% increase from $14.2 million in 2024. The company achieved net income of $1.2 million, a substantial improvement from $74,000 in the prior year. Gross margin expanded to $11.6 million (61.9% gross margin) from $8.7 million (61.6% gross margin). Operating income reached $1.1 million compared to just $6,000 in 2024. The company generated positive operating cash flow of $1.6 million and ended the year with $5.4 million in cash and cash equivalents, up from $3.8 million at the end of 2024. Total assets increased to $13.6 million from $11.2 million, while total liabilities remained manageable at $3.4 million.

Revenue Analysis

Revenue growth was primarily driven by product sales, which increased to $18.2 million from $14.0 million in 2024, representing 30% growth. Royalty and other revenues also increased significantly to $555,000 from $127,000. The company serves multiple markets including hospitals and healthcare facilities, dialysis settings, and foodservice/hospitality. Medical filtration products, which are FDA 510(k)-cleared Class II medical devices, represent the core business. The company noted that three major customers accounted for 44% of total revenues in 2025, with Customer A representing 22%, Customer B 12%, and Customer C 10% of revenues.

Margins & Profitability

Gross margin improved to 61.9% from 61.6% in the prior year, with gross profit increasing to $11.6 million from $8.7 million. Cost of goods sold was $7.2 million compared to $5.4 million in 2024. Operating expenses increased to $10.5 million from $8.7 million, primarily due to higher selling, general and administrative expenses of $9.0 million (up from $7.7 million) and increased research and development spending of $1.3 million (up from $906,000). Despite higher operating expenses, operating margin improved to 6.1% from near zero in 2024. The company maintained positive operating leverage as revenue growth outpaced expense growth.

Cash Flow & Balance Sheet

The company generated $1.6 million in operating cash flow, a significant improvement from negative $492,000 in 2024. Key drivers included net income of $1.2 million, adjustments for non-cash items including $296,000 in stock-based compensation, and working capital improvements. Investing activities were neutral, while financing activities used $5,000 for principal payments on finance lease liabilities. The balance sheet shows improved liquidity with current assets of $11.2 million and current liabilities of $2.8 million, resulting in a current ratio of approximately 4.0. Total stockholders' equity increased to $10.2 million from $8.6 million, primarily due to net income generation.

Outlook

The company faces several risk factors including dependence on a limited number of manufacturers, particularly Medica S.p.A. as the sole supplier for certain filter materials under a License and Supply Agreement that requires minimum annual purchases through 2030. The company must meet minimum purchase commitments of €4,976,000 for 2026, €5,349,000 for 2027, €5,750,000 for 2028, €6,000,000 for 2029, and €6,300,000 for 2030. Other risks include potential tariff impacts on imported materials, competition in water filtration markets, regulatory compliance requirements for medical devices, and dependence on key personnel. The company continues to focus on growth in medical and commercial filtration markets while managing expenses to maintain positive cash flow.